Topics:
Thoracic Malignancies • Medical Oncology
How do you sequence therapy for metastatic NSCLC patient with a BRAF V600E mutation?
Has the recent FDA approval of dabrafenib/trametinib changed your practice?
Answer from: Medical Oncologist at Academic Institution
In a newly diagnosed patient with metastatic NSCLC that harbors a BRAF V600E mutation, my preferred first line therapy is the combination of Dabrafenib plus Trametinib. My recommendation is based upon the high response rate (65%) of this combination observed in phase II trials. I would i...
Sign in or Register to read more